Sight Sciences (NASDAQ:SGHT) Issues Earnings Results, Misses Expectations By $0.05 EPS

by · The Cerbat Gem

Sight Sciences (NASDAQ:SGHT – Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.05), FiscalAI reports. The firm had revenue of $19.70 million for the quarter, compared to analyst estimates of $18.47 million. Sight Sciences had a negative return on equity of 49.92% and a negative net margin of 46.83%.

Here are the key takeaways from Sight Sciences’ conference call:

  • Raised revenue guidance: Q1 results drove Sight Sciences to raise full‑year 2026 revenue guidance to $83M–$89M (up from $82M–$88M), reflecting a return to double‑digit revenue growth across both segments.
  • Interventional Dry Eye (TearCare) early traction: TearCare revenue nearly doubled sequentially to $1.4M with ~1,500 SmartLids sold and utilization per active account rising from ~9 to ~16, driven partly by cross‑selling into existing glaucoma accounts.
  • Interventional Glaucoma (OMNI) momentum: OMNI delivered $18.3M in Q1 (+7% YoY), marking the third consecutive quarter of year‑over‑year growth, aided by Omni Edge adoption and continued focus on combo cataract and standalone markets.
  • Improved financial discipline and cash outlook: Adjusted operating expenses fell ~14% YoY, cash used in Q1 was $7M (down from $11.6M), ending cash was $85M, and management says it can reach cash‑flow breakeven without issuing new equity.
  • Patent judgment vs. Alcon: A final judgment upheld ~$55M in past damages plus ongoing 10% royalties on Hydrus sales, but no cash has been received and the ruling is subject to appeal, leaving the timing and cash impact uncertain.

Sight Sciences Stock Up 23.0%

SGHT traded up $0.99 during mid-day trading on Thursday, reaching $5.29. 430,052 shares of the stock were exchanged, compared to its average volume of 323,660. The company has a debt-to-equity ratio of 0.63, a quick ratio of 9.52 and a current ratio of 10.22. The company has a 50 day moving average price of $4.07 and a two-hundred day moving average price of $5.84. Sight Sciences has a 1 year low of $2.81 and a 1 year high of $9.24. The stock has a market capitalization of $287.78 million, a PE ratio of -7.45 and a beta of 2.38.

Analyst Ratings Changes

A number of brokerages have recently weighed in on SGHT. Stifel Nicolaus upped their target price on Sight Sciences from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Citigroup decreased their price target on shares of Sight Sciences from $9.10 to $6.50 and set a “neutral” rating for the company in a research note on Friday, March 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Sight Sciences in a report on Friday, April 10th. William Blair reaffirmed an “outperform” rating on shares of Sight Sciences in a research note on Thursday, March 5th. Finally, Cantor Fitzgerald set a $8.00 price objective on shares of Sight Sciences in a report on Monday, March 2nd. Five research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $8.31.

Check Out Our Latest Analysis on Sight Sciences

Sight Sciences News Roundup

Here are the key news stories impacting Sight Sciences this week:

Insider Activity

In other news, CEO Paul Badawi sold 29,244 shares of the firm’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $3.70, for a total transaction of $108,202.80. Following the completion of the sale, the chief executive officer directly owned 6,151,156 shares of the company’s stock, valued at $22,759,277.20. This trade represents a 0.47% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO James Rodberg sold 7,231 shares of Sight Sciences stock in a transaction on Monday, April 6th. The stock was sold at an average price of $3.55, for a total value of $25,670.05. Following the sale, the chief financial officer owned 230,939 shares in the company, valued at $819,833.45. The trade was a 3.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 61,273 shares of company stock worth $221,764. Corporate insiders own 30.90% of the company’s stock.

Institutional Investors Weigh In On Sight Sciences

Several large investors have recently modified their holdings of the stock. Virtu Financial LLC purchased a new stake in Sight Sciences in the fourth quarter worth $109,000. Invesco Ltd. purchased a new position in Sight Sciences during the fourth quarter valued at approximately $2,791,000. Occudo Quantitative Strategies LP purchased a new stake in Sight Sciences in the 4th quarter worth approximately $185,000. Millennium Management LLC increased its stake in Sight Sciences by 99.4% in the 4th quarter. Millennium Management LLC now owns 266,919 shares of the company’s stock worth $2,117,000 after acquiring an additional 133,073 shares during the last quarter. Finally, Bridgeway Capital Management LLC boosted its position in shares of Sight Sciences by 4.5% during the 4th quarter. Bridgeway Capital Management LLC now owns 100,733 shares of the company’s stock valued at $799,000 after acquiring an additional 4,300 shares during the last quarter. Hedge funds and other institutional investors own 55.51% of the company’s stock.

About Sight Sciences

(Get Free Report)

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.

Featured Stories